BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Beijing Bio-Targeting Therapeutics Technology readouts · Asse
 tMemo
X-WR-CALDESC:Upcoming readouts of studies Beijing Bio-Targeting Therapeutic
 s Technology's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06763965-2397@assetmemo.bio
DTSTAMP:20261121T005933Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:BioTTT001: Phase 1/2 readout est. (NCT06763965)
DESCRIPTION:BioTTT001\, phase 1/2.\nStudy: Evaluating the Safety and Effica
 cy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.\
 nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/biottt001#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06763965
URL:https://assetmemo.bio/drug/biottt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
